Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

4.220 -0.110 (-2.54%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals Inc

< Previous 1 2 3 Next >
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives First Product Approval in China
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Second Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2023 Results on August 4, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Complete Response Letter for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2023 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports First Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2023 Results on May 5, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Strategic European Partnership with Orion Corporation
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Third Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives FDA Approval for Leuprolide Acetate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.